SEC Form 4

П

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

1. Name and Addres <u>WALTON AI</u>	ss of Reporting Perso LAN <u>G</u>	n*	2. Issuer Name and Ticker or Trading Symbol <u>ACADIA PHARMACEUTICALS INC</u> [ACAD]		tionship of Reporting Perso all applicable) Director Officer (give title	10% Owner Other (specify	
(Last) (First) (Middle) 315 POST ROAD WEST		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/12/2009		below)	below)	
(Street) WESTPORT	СТ	06880	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting		
(City)	(State)	(Zip)			Person		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)	ction	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)				(I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of									7. Title and Amount of Securities		8. Price of Derivative	9. Number of derivative	10. Ownership	11. Nature of Indirect	
Security (Instr. 3)	or Exercise Price of Derivative Security	(Month/Day/Year)	if any (Month/Day/Year)	Code ((Month/Day/Year)		of Securities Underlying Derivative Security (Instr. 3 and 4)		Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$2.16	06/12/2009		Α		10,000		(1)	06/11/2019	Common Stock	10,000	\$0	10,000	D	
Stock Option (Right to Buy)	\$2.16	06/12/2009		A		34,722		(1)	06/11/2019	Common Stock	34,722	(2)	34,722	D	

Explanation of Responses:

1. One-fourth of the shares subject to the Stock Option shall vest and become exercisable at the end of each three-month period following June 12, 2009.

2. The Reporting Person has elected to convert an annual retainer fee of \$25,000 into a Stock Option under the terms of the Issuer's Outside Director Compensation Program.

Remarks:

This Form 4 was executed by Raymond Charest on behalf of Alan G. Walton pursuant to a Power of Attorney which was filed with the Securities and Exchange Commission on June 17, 2008 in connection with the filing of a Form 4 for Acadia Pharmaceuticals Inc., which Power of Attorney is incorporated herein by reference.

<u>/s/ Raymond Charest Raymond</u> Charest, as Attorney-in-Fact for 06/16/2009 Alan G. Walton

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.